Modified Tat Oyi protein with enhanced immunogenicity
作者： Erwann Loret
DOI:
关键词: Virology 、 Peptide sequence 、 Immune system 、 Immunogenicity 、 Hiv 1 tat 、 Biology
摘要: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in patient, wherein the patient is administered with Tat protein comprising amino acid sequence SEQ ID NO: 1 2, variant thereof capable stimulating an immune response against proteins.
lens.org 参考文章(7)
Erwann Loret, Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein ,(2000)
Melanie Ott, Sara Pagans Lista, Acetylated tat polypeptides and methods of use thereof ,(2004)
Robert C Gallo, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years The Lancet. ,vol. 366, pp. 1894- 1898 ,(2005) , 10.1016/S0140-6736(05)67395-3
Dan H. Barouch, Challenges in the development of an HIV-1 vaccine Nature. ,vol. 455, pp. 613- 619 ,(2008) , 10.1038/NATURE07352
Sandrine Opi, Jean-Marie Péloponèse, Didier Esquieu, Jennifer Watkins, Grant Campbell, Jean de Mareuil, Kuan Teh Jeang, David L Yirrell, Pontiano Kaleebu, Erwann P Loret, Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine. ,vol. 22, pp. 3105- 3111 ,(2004) , 10.1016/J.VACCINE.2004.01.057
B. D. Walker, D. R. Burton, Toward an AIDS Vaccine Science. ,vol. 320, pp. 760- 764 ,(2008) , 10.1126/SCIENCE.1152622
Sandrine Opi, Jean-Marie Péloponèse, Didier Esquieu, Grant Campbell, Jean de Mareuil, Anne Walburger, Murielle Solomiac, Catherine Grégoire, Emmanuelle Bouveret, David L. Yirrell, Erwann P. Loret, Tat HIV-1 Primary and Tertiary Structures Critical to Immune Response Against Non-homologous Variants Journal of Biological Chemistry. ,vol. 277, pp. 35915- 35919 ,(2002) , 10.1074/JBC.M204393200